The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 15, 2025

Filed:

Jul. 10, 2019
Applicant:

Akamara Therapeutics, Inc., Philadelphia, PA (US);

Inventors:

Shiladitya Sengupta, Waltham, MA (US);

Aniruddha Sengupta, Delhi, IN;

Assignee:

Alyssum Therapeutic s, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/55 (2017.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 47/551 (2017.08); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/554 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/585 (2013.01);
Abstract

The present disclosure provides methods for treating cancer in a patient, comprising administering to the patient (i) a therapeutically effective amount of a compound of formula (VIII), or a pharmaceutically acceptable salt thereof, wherein Q, linker, and lipid are defined herein, and (ii) a therapeutically effective amount of an immune checkpoint inhibitor. Q-linker-lipid (VIII) In some embodiments, the compound is the following structure (10-125), or a pharmaceutically acceptable salt thereof: Pharmaceutical compositions comprising a compound of formula (VIII), such as 10-125, or a pharmaceutically acceptable salt thereof, an immune checkpoint inhibitor, and a pharmaceutically acceptable excipient are also described.


Find Patent Forward Citations

Loading…